As part of a national stockpiling process, the U.S. government is looking to companies in California and Britain for experimental anthrax vaccines.
U.S. Congressman Mike Rogers says he doesn't understand why it's happening. Rogers says he's hoping it's an oversight in the way the government has requested a competitive bid for the next generation of vaccinations.
The announcement comes just weeks after the government agreed to purchase close to $30 million worth of BioPort's product for use in the military. Development of an experimental vaccine won't affect the agreement. When it comes to stockpiling, the government may be looking for a more effective vaccination.
Kim Brennen Root, spokesperson for BioPort Corporation, says her company is working with the Centers for Disease Control and Prevention to reduce the number of doses in the vaccination process. Currently, six doses are required over a period of 18 months, but in time it may be reduced to three doses.